Background/Aims: Hydrothorax is a complication of continuous ambulatory peritoneal dialysis (CAPD) occurring due to pleuroperitoneal fistulae. Several treatments exist with no consensus as to best management. We report on the largest series of video-assisted thoracoscopic surgery (VATS) treated pleuroperitoneal fistulae yet available. Methods: Between 1995 and 2000, we treated 6 CAPD patients for acute right hydrothoraces using VATS. Data pertaining to size and sterility of hydrothoraces, presence of diaphragmatic defects, surgical procedures performed, morbidity and return to CAPD were obtained. Results: Hydrothoraces were drained in all patients and there were no significant growths on subsequent culture. Fistulae were directly identified and closed in three patients. In the remaining patients, endoclips were placed across the base of small diaphragmatic blebs (the presumed site of communication). Parietal pleurectomy was performed uneventfully in all patients. There was no morbidity, all patients returned to haemodialysis and there have been no recurrences. Conclusion: Pleuroperitoneal fistulae produce symptomatic hydrothoraces in CAPD patients. A variety of approaches to the problem have been described. This is the largest series of VATS available and shows the usefulness of this approach in both closing the defect and producing an effective pleurectomy to prevent recurrence.

1.
Cameron JI, Whiteside C, Katz J, Devins GM: Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am J Kidney Dis 2000;35(4):629–637.
2.
Berlyne GM, Lee HA, Ralston AJ, Woolwock JA: Pulmonary complications of peritoneal dialysis. Lancet 1966;75:2.
3.
Prats D, Fereres J, Vidour F, De Paula A, Naranjo P, Rentero R: Derrame subpulmonar como complication de la dialysis peritoneal. Rev Clin Exp 1974;47:135.
4.
Edwards SR, Unger AM: Acute hydrothorax: A new complication of peritoneal dialysis. J Am Med Assoc 1967;853:199.
5.
Le Veen HH, Piccone VA, Hutto RB: Management of ascites with hydrothorax. Am J Surg 1984;148:210–213.
6.
Green A, Logan M, Medawar W, McGrath F, Keeling F, Carmody M, Donohoe J: The management of hydrothorax in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990;10:271–274.
7.
Townsend R, Fragula J: Hydrothorax in a patient receiving CAPD. Arch Intern Med 1982;142:1571–1572.
8.
Jagasia MH, Cole FH, Stegman MH, Deaton P, Kennedy L: Video-assisted talc pleurodesis in the management of pleural effusion secondary to continuous ambulatory peritoneal dialysis: A report of three cases. Am J Kidney Dis 1996;28:772–774.
9.
Okada H, Ryuzaki M, Kotaki S, Nakamoto H, Sugahara S, Kaneko K, Yamamoto T, Kawahara H, Suzuki H: Thoracoscopic surgery and pleurodesis for pleuroperitoneal communication in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1999;34:170–172.
10.
Lee BF, Chang JM, Chui NT, Huang YF, Yang CC, Liu JC, Yu HS: Peritoneoscintigraphy using Tc-99m MAA for diagnosis of diaphragmatic disruption in a peritoneal dialysis patient. Kaohsiung J Med Sci 1997;13:695–699.
11.
Di Bisceglie M, Paladini P, Voltolini L, Garosi G, Ghiribelli C, Di Paolo N, Gotti G: Videothorascopic obliteration of pleuroperitoneal fistula in continuous peritoneal dialysis. Ann Thorac Surg 1996;62:1509–1510.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.